home > events calendar > more about event

Clinical Trial Supply Europe 2018


14-15 March 2018
Milan, Italy

 CTS Europe will be returning for the 19th edition next March. This prestigious event will welcome representatives from 6 of the top 10 pharmaceutical companies in Europe, who will be joined by leading biotech companies across the continent to jointly find solutions for your clinical trial supply problems and discuss changes in the industry.

As a streamed event this conference promises to address a larger variety of topics, with sessions covering all the essentials in clinical supply, from maximising forecasting software to patient centric strategies for supply chain and considering methods to achieve last mile delivery.

2018 Agenda Highlights:

·        Workshop: Assessing value in e-label technology to expedite packaging and labelling timeliness

·        Unpacking how patient centricity will change the clinical supply chain and how to prepare for this

·        Debate: Determining the value of building internal IRT systems vs purchasing ‘off the shelf’

·        Digitalizing clinical manufacturing; reducing waste, minimize human error and improving efficiency

·        Exploring various comparator sourcing models to determine which is most cost effective and cases least disruption to your supply

2018 Key Speakers:

·        Jan-Pieter Kappelle, Senior Director, Clinical Trial Supplies, UCB

·        Henk Mollee, Senior Director, CTM Manufacturing, Astellas Pharmaceuticals

·        Niklas Mattsson, Lead Comparator Sourcing and Planning, MSD

·        Alison Meyers, Director Clinical Liaison Lead, Clinical Interface, GlaxoSmithKline

·        Ross MacRae, Senior Director Clinical Manufacturing, Pfizer

·        Erik Meyer, Director Clinical Trial Supply, Merck

·        Peter Orosz, Head of Clinical Supply Chain Management & Oncology, Boehringer Ingelheim

·        Alex Robertson, Senior Director, Supply Chain Management, AstraZeneca

For more information, please visit: alternatively email us at:

phone +44 (0)207 936 6400
email Milan, Italy
Print this page
Send to a friend
Industry Events

14th Annual Biomarkers & Immuno-Oncology World Congress

11-13 June 2018, Westin Boston Waterfront, Boston, Massachusetts

The Biomarkers and Immuno-Oncology World Congress brings together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers—making the Congress a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

Banner of ChinaBio_Events_102 on Samedan
White Papers

Autoinjectors From Planning to Launch

SHL Group

Looking at the rising trend towards self-administration therapies, injectable drug delivery devices such as pen injectors, autoinjectors and needle free injectors show a significant growth potential in the near future. In 2010, the pen systems and autoinjectors market was estimated to be worth over $0.58bn, a growth of 8-10% from previous years. It is estimated that the market will continue to grow steadily between 10-15% over the forecast period. It will reach $0.87bn in 2013 and $1.07bn in 2015. (Visiongain, June, 2011)
More info >>

News and Press Releases

MSD launches ONTRUZANT®▼ (biosimilar trastuzumab), a biosimilar of intravenous HERCEPTIN®, which is the first breast cancer biosimilar in the UK

Hoddesdon, [8th March 2018] – MSD today announced the launch of ONTRUZANT®▼, (trastuzumab), a biosimilar referencing HERCEPTIN®* (trastuzumab/TRZ), for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer. This was the first trastuzumab biosimilar to receive regulatory approval in Europe and is the first to launch in the UK.1
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement